The FDA approved Roche’s cobas HPV test for first-line screening of cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, commonly used in Pap tests.

New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

Roche cobas HPV Test gained U.S. Food and Drug Administration (FDA) approval for the use with SurePath Preservative Fluid to detect human papilloma virus (HPV) in cervical cells. SurePath is one of ...

A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...

(RTTNews) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World Health Organization (WHO) ...

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 ...

The Roche cobas HPV Test has been approved by the FDA. A new HPV screening test that uses cervical cells collected for a Pap test has been approved by the FDA. The FDA has approved the Roche cobas HPV ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) approved the cobas ® HPV (Human Papillomavirus) Test for use as a first-line primary screening test ...

TROY, Mont.--(BUSINESS WIRE)-- In an April 22, 2011 letter to FDA Commissioner; Dr. Margaret Hamburg, Norma Erickson on behalf of the SaneVax Inc. Board of Directors, criticized the FDA for not ...

New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...